| Patent application number | Description | Published |
|---|
| 20090123473 | HUMAN BNP IMMUNOSPECIFIC ANTIBODIES - The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies. | 05-14-2009 |
| 20090123946 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 05-14-2009 |
| 20090124022 | ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies. | 05-14-2009 |
| 20090148866 | Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase - The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample. | 06-11-2009 |
| 20090203037 | Anti-T. Cruzi Antibodies and Methods of Use - The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of | 08-13-2009 |
| 20090263894 | ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies. | 10-22-2009 |
| 20090269777 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 10-29-2009 |
| 20100227775 | IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample. | 09-09-2010 |
| 20100266575 | SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING - An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid. | 10-21-2010 |
